StockData
TG Therapeutics, Inc. logo

TG Therapeutics, Inc. (TGTX) stock

TGTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 9/303% above fair value
$66.12+3.41 (+5.44%)

Close on Nov 18, 2026Market cap $10.12BP/E 24.1Yield –

TG Therapeutics cash

Cash and short-term investments held at the end of each period.

TG Therapeutics's cash was $612.30M at Jun 30, 2026. For fiscal 2025 it was $199.50M, down 35.9% from the year before. Over ten years it grew 6.9% a year on average. The highest annual figure on record is $605.40M in fiscal 2020.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$199.50M-35.9%
FY2024Dec 31, 2024$311.00M+43.0%
FY2023Dec 31, 2023$217.50M+24.9%
FY2022Dec 31, 2022$174.10M-50.3%
FY2021Dec 31, 2021$350.30M-42.1%
FY2020Dec 31, 2020$605.40M+331.2%
FY2019Dec 31, 2019$140.40M+100.2%
FY2018Dec 31, 2018$70.14M-17.8%
FY2017Dec 31, 2017$85.30M+87.6%
FY2016Dec 31, 2016$45.47M-55.6%
FY2015Dec 31, 2015$102.40M+29.8%
FY2014Dec 31, 2014$78.86M+73.6%
FY2013Dec 31, 2013$45.43M+176.1%
FY2012Dec 31, 2012$16.46M+68.8%
FY2011Dec 31, 2011$9.75M–
FY2010Dec 31, 2010$0–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$612.30M+119.5%
Q1 FY2026Mar 31, 2026$572.80M+107.4%
Q4 FY2025Dec 31, 2025$199.50M-35.9%
Q3 FY2025Sep 30, 2025$178.30M-47.7%
Q2 FY2025Jun 30, 2025$278.90M+28.3%
Q1 FY2025Mar 31, 2025$276.20M+31.6%
Q4 FY2024Dec 31, 2024$311.00M+43.0%
Q3 FY2024Sep 30, 2024$341.00M+48.8%
Q2 FY2024Jun 30, 2024$217.30M+50.0%
Q1 FY2024Mar 31, 2024$209.80M+50.2%
Q4 FY2023Dec 31, 2023$217.50M+24.9%
Q3 FY2023Sep 30, 2023$229.20M+15.9%
Q2 FY2023Jun 30, 2023$144.91M-37.5%
Q1 FY2023Mar 31, 2023$139.70M-50.2%
Q4 FY2022Dec 31, 2022$174.10M-50.3%
Q3 FY2022Sep 30, 2022$197.70M-48.2%
Q2 FY2022Jun 30, 2022$231.80M-49.2%
Q1 FY2022Mar 31, 2022$280.70M-46.4%
Q4 FY2021Dec 31, 2021$350.30M-42.1%
Q3 FY2021Sep 30, 2021$381.40M+50.0%
Q2 FY2021Jun 30, 2021$456.20M+65.5%
Q1 FY2021Mar 31, 2021$523.80M+569.0%
Q4 FY2020Dec 31, 2020$605.40M+331.2%
Q3 FY2020Sep 30, 2020$254.20M+250.9%
Q2 FY2020Jun 30, 2020$275.60M+224.3%
Q1 FY2020Mar 31, 2020$78.30M-15.3%
Q4 FY2019Dec 31, 2019$140.40M+100.2%
Q3 FY2019Sep 30, 2019$72.45M-25.9%
Q2 FY2019Jun 30, 2019$84.98M-32.7%
Q1 FY2019Mar 31, 2019$92.47M-15.3%
Q4 FY2018Dec 31, 2018$70.14M-17.8%
Q3 FY2018Sep 30, 2018$97.74M+6.5%
Q2 FY2018Jun 30, 2018$126.25M+45.9%
Q1 FY2018Mar 31, 2018$109.20M-0.3%
Q4 FY2017Dec 31, 2017$85.30M+87.6%
Q3 FY2017Sep 30, 2017$91.80M+51.2%
Q2 FY2017Jun 30, 2017$86.50M–
Q1 FY2017Mar 31, 2017$109.50M–
Q4 FY2016Dec 31, 2016$45.47M–
Q3 FY2016Sep 30, 2016$60.70M–

More TG Therapeutics figures

See a number that looks wrong?